🇺🇸 Ifosfamide for Injection in United States
206 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 206
Most-reported reactions
- Febrile Neutropenia — 89 reports (43.2%)
- Malignant Neoplasm Progression — 19 reports (9.22%)
- Disease Progression — 16 reports (7.77%)
- Product Use In Unapproved Indication — 15 reports (7.28%)
- Respiratory Failure — 13 reports (6.31%)
- Encephalopathy — 12 reports (5.83%)
- Sepsis — 12 reports (5.83%)
- Mucosal Inflammation — 11 reports (5.34%)
- Pyrexia — 10 reports (4.85%)
- Off Label Use — 9 reports (4.37%)
Other Oncology approved in United States
Frequently asked questions
Is Ifosfamide for Injection approved in United States?
Ifosfamide for Injection does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Ifosfamide for Injection in United States?
BeBetter Med Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.